{"id":935461,"date":"2026-02-10T07:27:06","date_gmt":"2026-02-10T12:27:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/astrazeneca-results-fy-and-q4-2025\/"},"modified":"2026-02-10T07:27:06","modified_gmt":"2026-02-10T12:27:06","slug":"astrazeneca-results-fy-and-q4-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/astrazeneca-results-fy-and-q4-2025\/","title":{"rendered":"AstraZeneca results: FY and Q4 2025"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwalignr { text-align: right; list-style-position: inside }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwlistdecimal { list-style-type: decimal }\n.bwlistdisc { list-style-type: disc }\n.bwpadb3 { padding-bottom: 4px }\n.bwpadl0 { padding-left: 0px }\n.bwpadl1 { padding-left: 5px }\n.bwpadr0 { padding-right: 0px }\n.bwsinglebottom { border-bottom: solid black 1pt }\n.bwtablemarginb { margin-bottom: 10px }\n.bwtopsingle { border-top: solid black 1pt }\n.bwuline { text-decoration: underline }\n.bwvertalignb { vertical-align: bottom }\n.bwvertalignt { vertical-align: top }\n.bwwidth100 { width: 100% }\n.bwwidth12 { width: 12% }\n.bwwidth14 { width: 14% }\n.bwwidth18 { width: 18% }\n.bwwidth32 { width: 32% }\n.bwwidth40 { width: 40% }\n.bwwidth46 { width: 46% }\n.bwwidth8 { width: 8% }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p>\nAstraZeneca results: FY and Q4 2025<\/p>\n<p><b>Strong commercial performance and excellent pipeline delivery in a continuing catalyst-rich period<\/b><\/p>\n<p>CAMBRIDGE, England&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nAstraZeneca:<\/p>\n<p><b>Revenue and EPS summary<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwwidth32 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwtopsingle bwpadl0 bwwidth14\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>FY 2025<\/b><\/p>\n<\/td>\n<td colspan=\"2\" class=\"bwtopsingle bwpadl0\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\"><b>% Change<\/b><\/p>\n<\/td>\n<td class=\"bwtopsingle bwpadl0 bwwidth14\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>Q4 2025<\/b><\/p>\n<\/td>\n<td colspan=\"2\" class=\"bwtopsingle bwpadl0\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\"><b>% Change<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth32 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwwidth14\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>$m<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwwidth12\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>Actual<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwwidth8\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>CER<\/b><sup>1<\/sup><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwwidth14\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>$m<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwwidth12\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>Actual<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwwidth8\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>CER<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth32 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>&#8211; Product Sales<\/i><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth14\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><i>55,573<\/i><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth12\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><i>9<\/i><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth8\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><i>9<\/i><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth14\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><i>14,538<\/i><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth12\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><i>9<\/i><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth8\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><i>7<\/i><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth32 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>&#8211; Alliance Revenue<\/i><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth14\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><i>3,067<\/i><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth12\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><i>39<\/i><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth8\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><i>38<\/i><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth14\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><i>959<\/i><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth12\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><i>34<\/i><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth8\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><i>33<\/i><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth32 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nProduct Revenue<sup>2<\/sup><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth14\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n58,640<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth12\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n10<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth8\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n10<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth14\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n15,497<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth12\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n10<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth8\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n8<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth32 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nCollaboration Revenue<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth14\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n99<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth12\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(89)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth8\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(89)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth14\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n6<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth12\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(99)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth8\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(99)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth32 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Total Revenue<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth14\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>58,739<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth12\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>9<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth8\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>8<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth14\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>15,503<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth12\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>4<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth8\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>2<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth32 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Reported EPS ($)<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth14\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>6.60<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth12\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>45<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth8\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>43<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth14\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>1.50<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth12\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>55<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth8\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>47<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth32 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Core<\/b><sup>3<\/sup><b>EPS<sup \/>($)<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth14\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>9.16<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth12\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>12<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth8\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>11<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth14\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>2.12<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth12\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>1<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth8\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>(2)<\/b><\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p><b><span class=\"bwuline\">Key performance elements for FY 2025<\/span><\/b><\/p>\n<p>\n(Growth numbers at constant exchange rates)<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nTotal Revenue up 8% to $58,739m, driven by Oncology, CVRM, R&amp;I and Rare Disease<\/p>\n<\/li>\n<li>\nGrowth in Total Revenue across all major geographic regions<\/p>\n<\/li>\n<li>\nCore Operating profit increased 9%<\/p>\n<\/li>\n<li>\nCore EPS increased 11% to $9.16<\/p>\n<\/li>\n<li>\nSecond interim dividend declared of $2.17 per share (159.5 pence, 19.49 SEK). Total dividend declared for FY 2025 increased by 3% to $3.20 per share<\/p>\n<\/li>\n<li>\n16 positive Phase 3 readouts and 43 approvals in major regions in the last twelve months<\/p>\n<\/li>\n<\/ul>\n<p><b><span class=\"bwuline\">Pascal Soriot, Chief Executive Officer, AstraZeneca, said:<\/span><\/b><\/p>\n<p>\n&#8220;In 2025 we saw strong commercial performance across our therapy areas and excellent pipeline delivery. We announced the results of 16 positive Phase 3 studies during the year and now have 16 blockbuster medicines.<\/p>\n<p>\nThe momentum across our company is continuing in 2026 and we are looking forward to the results of more than 20 Phase 3 trial readouts this year. We have more than 100 Phase 3 studies ongoing, including a substantial and growing number of trials of our transformative technologies which have the potential to revolutionise outcomes for patients and drive our growth well beyond 2030.<\/p>\n<p>\nLastly, ordinary shares in our company began trading on the NYSE on the 2nd February, resulting in a harmonised listing structure across exchanges in London, New York and Stockholm, enabling more shareholders to participate in our company&#8217;s exciting future.&#8221;<\/p>\n<p><b><span class=\"bwuline\">Guidance<\/span><\/b><\/p>\n<p>\nAstraZeneca issues Total Revenue and Core EPS guidance<sup>4<\/sup> for FY 2026 at CER, based on the average foreign exchange rates through 2025.<\/p>\n<p class=\"bwalignc\"><b>Total Revenue<\/b> is expected to increase by a <b>mid-to<\/b>&#8211;<b>high single-digit<\/b> percentage<br \/>\n<br \/><b>Core EPS<\/b> is expected to increase by a <b>low double-digit<\/b> percentage<\/p>\n<p>\nThe Core Tax rate is expected to be between 18-22%<\/p>\n<p>\nIf foreign exchange rates for February 2026 to December 2026 were to remain at the average rates seen in January 2026, it is anticipated that Total Revenue in FY 2026 would benefit from a low single-digit percentage positive impact compared to the performance at CER, and Core EPS growth would be broadly similar to the growth at CER.<\/p>\n<p><b>Results highlights<\/b><\/p>\n<p><b>Table 1: Milestones achieved since the prior results announcement<br \/>\n<br \/><\/b>Phase III and other registrational data readouts<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwtopsingle bwsinglebottom bwwidth18 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Medicine<\/b><\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Trial<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwpadl0 bwwidth46\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Indication<\/b><\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Event<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth18 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nceralasertib + <i>Imfinzi<\/i><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nLATIFY<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth46\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nPost-IO NSCLC<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nPrimary endpoint not met<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth18 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nbaxdrostat<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nBaxAsia<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth46\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nTreatment resistant hypertension<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nPrimary endpoint met<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\nRegulatory approvals<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwtopsingle bwsinglebottom bwwidth18 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Medicine<\/b><\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Trial<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwpadl0 bwwidth46\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Indication<\/b><\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Region<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth18 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>Enhertu<\/i><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nDESTINY-Gastric04<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth46\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\n2L HER2+ gastric\/GEJ cancer<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nEU, CN<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth18 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>Enhertu<\/i><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nDESTINY-Breast09<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth46\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\n1L HER2+ mBC<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nUS<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth18 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>Enhertu<\/i><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nDESTINY-Breast06<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth46\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nCTx na\u00efve HER2-low and -ultralow mBC<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nCN<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth18 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>Imfinzi<\/i><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nPACIFIC-5<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth46\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nStage III NSCLC<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nCN<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth18 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>Imfinzi<\/i><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nMATTERHORN<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth46\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nResectable gastric\/GEJ cancer<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nUS<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth18 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>Imfinzi<\/i><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nDUO-E<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth46\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\ndMMR endometrial cancer<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nCN<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth18 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>Wainua<\/i><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nNEURO-TTRANSFORM<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth46\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nATTRv-PN<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nCN<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth18 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>Fasenra<\/i><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nMANDARA<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth46\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nEGPA<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nCN<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth18 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>Saphnelo<\/i><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nTULIP-SC<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth46\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nSLE (subcutaneous)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nEU<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth18 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>Koselugo<\/i><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nKOMET<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth46\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nAdult patients with NF1-PN<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nUS<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth18 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>Koselugo<\/i><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nSPRINKLE<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth46\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nPaediatric patients with NF1-PN (granule formulation)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nEU<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth18 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>Soliris<\/i><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nNCT03759366<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth46\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\ngMG (paediatric patients)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nCN<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\nRegulatory submissions or acceptances* in major regions<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwtopsingle bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Medicine<\/b><\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Trial<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwpadl0 bwwidth46\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Indication<\/b><\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Region<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>Datroway<\/i><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nTROPION-Breast02<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth46\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nMetastatic TNBC not candidates for IO<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nUS, EU, CN<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>Enhertu<\/i><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nDESTINY-Breast09<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth46\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\n1L HER2+ mBC<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nEU<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>Ultomiris<\/i><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nALXN1210-PNH-323<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth46\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nPNH<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nCN<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nbaxdrostat<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nBaxHTN \/ Bax24<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth46\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nTreatment resistant hypertension<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nUS, EU<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\ngefurulimab<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nPREVAIL<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth46\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nGeneralised myasthenia gravis<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nUS, EU, CN<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nanselamimab<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nCARES<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth46\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nKappa light chain amyloidosis<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth18\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nEU, JP<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p><i>* US, EU and China regulatory submissions denotes filing acceptance<\/i><\/p>\n<p><b><span class=\"bwuline\">Other pipeline updates<\/span><\/b><\/p>\n<p>\nFor recent trial starts and anticipated timings of key trial readouts, please refer to the Clinical Trials Appendix document in the financial results section of the AstraZeneca investor relations website: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.astrazeneca.com%2Finvestor-relations.html&amp;esheet=54421459&amp;newsitemid=20260209280778&amp;lan=en-US&amp;anchor=www.astrazeneca.com%2Finvestor-relations.html&amp;index=1&amp;md5=3eebab28a74d01663f3fd65fb6a45c65\">www.astrazeneca.com\/investor-relations.html<\/a>.<\/p>\n<p><b>Table 2: Key elements of financial performance: Q4 2025<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwtopsingle bwwidth12 bwpadl1 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nFor the<b> quarter<\/b><\/p>\n<\/td>\n<td class=\"bwtopsingle bwpadl0 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>Reported<\/b><\/p>\n<\/td>\n<td colspan=\"2\" class=\"bwvertalignt bwtopsingle bwpadl0\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\"><b>Change<\/b><\/p>\n<\/td>\n<td class=\"bwtopsingle bwpadl0 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>Core<\/b><\/p>\n<\/td>\n<td colspan=\"2\" class=\"bwvertalignt bwtopsingle bwpadl0\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\"><b>Change<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwwidth40 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth12 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nended 31 December<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth8\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>$m<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth8\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>Act<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth8\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>CER<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth8\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>$m<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth8\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>Act<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth8\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>CER<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwwidth40 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth12 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nProduct Revenue<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n15,497<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n10<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n8<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n15,497<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n10<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n8<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwwidth40 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u2022 See Tables 3, 7, 29 and 30 for further details of Product Revenue, Product Sales and Alliance Revenue<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth12 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nCollaboration Revenue<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n6<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(99)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(99)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n6<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(99)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(99)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwwidth40 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p>\n\u2022 See Tables 4 and 31 for details of Collaboration Revenue<br \/>\n<br \/>\u2022 In Q4 2024, $815m of Collaboration Revenue was recognised as <i>Lynparza, Beyfortus <\/i>and <i>Koselugo<\/i> each achieved a sales-based milestone<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth12 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nTotal Revenue<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n15,503<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n4<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n2<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n15,503<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n4<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n2<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwwidth40 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u2022 See Tables 5 and 6 for Total Revenue by Therapy Area and by region<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth12 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nGross Margin (%)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n80<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth8\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n-2pp<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth8\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n-2pp<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n80<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth8\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n-2pp<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth8\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n-2pp<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwwidth40 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p>\n\u2212 Cost of sales included a $235m expense in Q4 2025 for royalty buyout expenses relating to <i>Saphnelo<\/i> and rilvegostomig (see page 5, &#8216;Corporate and business development&#8217; for details)<br \/>\n<br \/>\u2022 Variations in Gross Margin can be expected between periods due to various factors, including fluctuations in foreign exchange rates, product seasonality and Collaboration Revenue<br \/>\n<br \/>\u2022 See &#8216;Reporting changes since FY 2024&#8217; on page 6 for the definition of Gross Margin<sup>5<\/sup><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth12 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nR&amp;D expense<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n3,862<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(17)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(19)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n3,731<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n4<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n3<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwwidth40 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u2022 Core R&amp;D: 24% of Total Revenue<br \/>\n<br \/>+ Accelerated recruitment in ongoing trials<br \/>\n<br \/>+ Investments in transformative technologies such as IO bispecifics, cell therapy and antibody drug conjugates<br \/>\n<br \/>+ Addition of R&amp;D projects from business development<br \/>\n<br \/>+ Positive data readouts for high value pipeline opportunities that have ungated large late-stage trials<br \/>\n<br \/>\u2212 Reported R&amp;D expense decreased due to impairment charges in Q4 2024<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth12 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nSG&amp;A expense<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n5,492<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n2<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n&#8211;<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n4,453<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n4<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n2<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwwidth40 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u2022 Core SG&amp;A: 29% of Total Revenue<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth12 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nOther operating income and expense<sup>6<\/sup><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n100<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n&#8211;<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n2<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n101<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n2<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n2<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwwidth40 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth12 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nOperating Profit<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n2,978<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n46<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n40<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n4,098<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(2)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(5)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwwidth40 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u2212 Operating Profit includes the $235m royalty buyout expensed in Cost of sales (see above)<br \/>\n<br \/>+ Reported Operating Profit includes R&amp;D impairment charges in Q4 2024<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth12 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nOperating Margin (%)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n19<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth8\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n+6pp<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth8\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n+5pp<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n26<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth8\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n-2pp<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth8\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n-2pp<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwwidth40 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth12 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nNet finance expense<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n349<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(4)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(2)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n269<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(13)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(10)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwwidth40 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u2212 Adjustment of interest on tax and maturity of debt during Q4 2025<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth12 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nTax rate (%)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n11<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth8\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n+1pp<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth8\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n+1pp<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n14<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth8\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n-2pp<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth8\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n-2pp<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwwidth40 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u2022 Variations in the tax rate can be expected between periods<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwwidth12 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nEPS ($)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n1.50<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n55<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n47<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n2.12<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n1<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth8 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(2)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwwidth40 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u2212 Year-on-year comparison reflects the sales-based milestones recognised in Q4 2024<br \/>\n<br \/>+ Reported EPS benefitted from reduction in R&amp;D impairments<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p><i>For monetary values the unit of change is percent. For Gross Margin, Operating Margin and Tax rate, the unit of change is percentage points (pp).<\/i><\/p>\n<p><i>In the expense commentary above, the plus and minus symbols denote the directional impact of the item being discussed, e.g. a &#8216;+&#8217; symbol beside an R&amp;D expense comment indicates that the item increased R&amp;D expenditure relative to the prior year period.<\/i><\/p>\n<p><b><span class=\"bwuline\">Corporate and business development<\/span><\/b><\/p>\n<p><b>Jacobio Pharma<\/b><\/p>\n<p>\nIn December 2025, Jacobio Pharma announced that it has entered an agreement with AstraZeneca for its proprietary Pan-KRAS inhibitor JAB-23E73.<\/p>\n<p>\nAstraZeneca will receive exclusive development and commercialisation rights outside of China, while AstraZeneca and Jacobio Pharma will jointly develop and commercialise JAB-23E73 in China.<\/p>\n<p>\nUnder the terms of the agreement, Jacobio will receive an upfront payment of $100m, and is eligible for additional development and commercial milestone payments of up to $1.9bn, as well as tiered royalties on net sales achieved outside of China. AstraZeneca will be responsible for all clinical development, regulatory submissions, and commercialisation activities for JAB-23E73 outside of China.<\/p>\n<p><b>Modella AI<\/b><\/p>\n<p>\nIn Q4 2025, Modella AI was acquired by AstraZeneca. The acquisition will embed Modella AI&#8217;s multi-modal foundation models and AI agents into AstraZeneca&#8217;s oncology R&amp;D environment.<\/p>\n<p><b>BMS<\/b><\/p>\n<p>\nIn Q4 2025, AstraZeneca paid Bristol-Myers Squibb Company (BMS) $170m, expensed in Cost of sales, in exchange for the reduction to zero of all royalties payable on <i>Saphnelo<\/i> sales ex-US. Royalties on US sales will remain payable at a mid-teens percentage.<\/p>\n<p><b>Compugen<\/b><\/p>\n<p>\nIn Q4 2025, AstraZeneca paid Compugen Ltd. (Compugen) $65m, expensed in Cost of sales, and agreed a potential additional $25m upon the next milestone payment on BLA acceptance, for a portion of Compugen&#8217;s existing royalty interest in rilvegostomig. AstraZeneca will pay tiered royalties of up to mid-single digits on future sales.<\/p>\n<p><b>AbelZeta<\/b><\/p>\n<p>\nIn January 2026, AbelZeta Pharma, Inc. (AbelZeta) announced that AstraZeneca has agreed to acquire AbelZeta&#8217;s 50% share of the China development and commercialisation rights to C-CAR031, an autologous, Glypican 3 (GPC3)-targeting chimeric antigen receptor T-Cell therapy.<\/p>\n<p>\nFollowing completion of this agreement, AstraZeneca will have the sole right to develop, manufacture and commercialise C-CAR031 globally. AbelZeta will be entitled to receive up to $630m from AstraZeneca including an upfront payment, and development, regulatory and sales milestone payments for the GPC3 program in China.<\/p>\n<p><b>China investment plans<\/b><\/p>\n<p>\nIn January 2026, AstraZeneca announced plans to invest $15bn in China through 2030 to expand medicines manufacturing and R&amp;D. These investments build on AstraZeneca&#8217;s substantial footprint in China, including global strategic R&amp;D centres in Beijing and Shanghai.<\/p>\n<p><b>Listing harmonisation<\/b><\/p>\n<p>\nOn 2 February 2026, AstraZeneca began trading its ordinary shares on the New York Stock Exchange (NYSE), enabling more US investors to participate in the Company&#8217;s strong growth. Trading in AstraZeneca ordinary shares is now aligned across the NYSE, the London Stock Exchange and Nasdaq Stockholm under a harmonised listing structure.<\/p>\n<p>\nThe prior listing of American Depositary Shares on Nasdaq in the US ceased on 30 January 2026.<\/p>\n<p><b>CSPC<\/b><\/p>\n<p>\nIn January 2026, AstraZeneca announced a new strategic collaboration agreement with CSPC Pharmaceuticals. AstraZeneca will receive exclusive global rights outside of China to CSPC&#8217;s once-monthly injectable weight management portfolio, including SYH2082, a long-acting GLP-1R\/GIPR agonist progressing into Phase I, and three preclinical programmes. CSPC will receive an upfront payment of $1.2bn and is eligible to receive development and regulatory milestones of up to $3.5bn across all programmes. CSPC will also be eligible for further commercialisation and sales milestones plus tiered royalties.<\/p>\n<p><b><span class=\"bwuline\">Sustainability highlights<\/span><\/b><\/p>\n<p>\nFor the tenth year, AstraZeneca was recognised by CDP for climate action and water stewardship, receiving an A for Climate and A- for Water Security in 2025. This reflects the Company&#8217;s significant progress in decarbonising and reducing its environmental footprint.<\/p>\n<p>\nThe Sustainable Markets Initiative (SMI) Health Systems Task Force, chaired by AstraZeneca CEO Pascal Soriot, supported the development and launch of <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bsigroup.com%2Fen-GB%2Finsights-and-media%2Fmedia-centre%2Fpress-releases%2F2025%2Fdecember%2Ffirst-global-standard-for-measuring-the-environmental-impact-of-pharmaceuticals-published%2F%23%3A%7E%3Atext%3DDeveloped%2520through%2520collaboration%2520across%2520the%2Cand%2520reduce%2520their%2520product%2520footprints.&amp;esheet=54421459&amp;newsitemid=20260209280778&amp;lan=en-US&amp;anchor=PSA+2090&amp;index=2&amp;md5=e1ef698076a735b7f139b6ea819b657c\">PSA 2090<\/a>, the world&#8217;s first global standard to measure and assess the environmental impact of pharmaceutical products through their lifecycle.<\/p>\n<p><b><span class=\"bwuline\">Reporting calendar<\/span><\/b><\/p>\n<p>\nThe Company intends to publish its Q1 2026 results on 29 April 2026.<\/p>\n<p><b><span class=\"bwuline\">Conference call<\/span><\/b><\/p>\n<p>\nA conference call and webcast for investors and analysts will begin today, 10 February 2026, at 11:45 UK time. Details can be accessed via <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.astrazeneca.com%2Finvestor-relations.html&amp;esheet=54421459&amp;newsitemid=20260209280778&amp;lan=en-US&amp;anchor=astrazeneca.com&amp;index=3&amp;md5=b2d215d4db07bca46602c23994fdf0b8\">astrazeneca.com<\/a>.<\/p>\n<p><b><span class=\"bwuline\">Reporting changes since FY 2024<\/span><\/b><\/p>\n<p><b>Product Revenue<\/b><\/p>\n<p>\nEffective 1 January 2025, the Group has updated the presentation of Total Revenue on the face of the Statement of Comprehensive Income to include a new subtotal &#8216;Product Revenue&#8217; representing the summation of Product Sales and Alliance Revenue.<\/p>\n<p>\nProduct Revenue and Collaboration Revenue form Total Revenue.<\/p>\n<p>\nProduct Sales and Alliance Revenue will continue to be presented separately, with the new subtotal providing additional aggregation of revenue types with similar characteristics, reflecting the growing importance of Alliance Revenue.<\/p>\n<p>\nFull descriptions of Product Sales, Alliance Revenue and Collaboration Revenue are included from page 152 of the Group&#8217;s <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.astrazeneca.com%2Fcontent%2Fdam%2Faz%2FInvestor_Relations%2Fannual-report-2024%2Fpdf%2FAstraZeneca_AR_2024.pdf&amp;esheet=54421459&amp;newsitemid=20260209280778&amp;lan=en-US&amp;anchor=Annual+Report+and+Form+20-F+Information+2024.&amp;index=4&amp;md5=0b1558c95db87fc2f8715a3d5eb9d10a\">Annual Report and Form 20-F Information 2024.<\/a><\/p>\n<p><b>Gross Margin<\/b><\/p>\n<p>\nEffective 1 January 2025, the Group has replaced the measure of &#8216;Product Sales Gross Margin&#8217; with the measure of &#8216;Gross Margin&#8217;. Previously, the measure excluded margin related to Alliance Revenue and Collaboration Revenue. The new measure is calculated using Gross profit as a percentage of Total Revenue, thereby encompassing all revenue categories, and is intended to provide a more comprehensive measure of total performance.<\/p>\n<p><b><span class=\"bwuline\">Notes<\/span><\/b><\/p>\n<ol class=\"bwlistdecimal\">\n<li>\nConstant exchange rates. The differences between Actual Change and CER Change are due to foreign exchange movements between periods in 2025 vs. 2024. CER financial measures are not accounted for according to generally accepted accounting principles (GAAP) because they remove the effects of currency movements from Reported results.<\/p>\n<\/li>\n<li>\nEffective 1 January 2025, the Group has updated its presentation of Total Revenue, adding a new subtotal of Product Revenue, the sum of Product Sales and Alliance Revenue. For further details, see Note 1: &#8216;Basis of preparation and accounting policies&#8217; in the Notes to the Condensed consolidated financial statements.<\/p>\n<\/li>\n<li>\nCore financial measures are adjusted to exclude certain items. The differences between Reported and Core measures are primarily due to costs relating to the amortisation of intangibles, impairments, legal settlements and restructuring charges. A full reconciliation between Reported EPS and Core EPS is provided in Tables 10 and 11 in the Financial Performance section of this document.<\/p>\n<\/li>\n<li>\nThe Company is unable to provide guidance on a Reported basis because it cannot reliably forecast material elements of the Reported results, including any fair value adjustments arising on acquisition-related liabilities, intangible asset impairment charges and legal settlement provisions. Please refer to the Cautionary statements section regarding forward-looking statements at the end of this announcement.<\/p>\n<\/li>\n<li>\nEffective 1 January 2025, the Group has updated its presentation of Gross Margin, which is defined as Gross Profit divided by Total Revenue. In prior years, the Group&#8217;s financial tables cited a different margin metric, Product Sales Gross Margin.<\/p>\n<\/li>\n<li>\nIncome from disposals of assets and businesses, where the Group does not retain a significant ongoing economic interest, is recorded in Other operating income and expense in the Group&#8217;s financial statements.<\/p>\n<\/li>\n<\/ol>\n<p>\nTo read AstraZeneca&#8217;s Full Year and Q4 2025 Financial Results press release in full, click <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.astrazeneca.com%2Fmedia-centre%2Fpress-releases%2F2026%2Ffull-year-q4-2025-results.html&amp;esheet=54421459&amp;newsitemid=20260209280778&amp;lan=en-US&amp;anchor=here&amp;index=5&amp;md5=9f3bbdda65fa88d33abfaf544f7820fc\">here<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260209280778r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260209280778\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260209280778\/en\/<\/a><\/span><\/p>\n<p>\nGlobal Media Relations team<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:global-mediateam@astrazeneca.com\">global-mediateam@astrazeneca.com<br \/>\n<\/a><br \/>+44 (0)1223 344 800<\/p>\n<p><b>KEYWORDS:<\/b> United Kingdom Europe<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260209280778\/en\/2301168\/3\/original.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca results: FY and Q4 2025 Strong commercial performance and excellent pipeline delivery in a continuing catalyst-rich period CAMBRIDGE, England&#8211;(BUSINESS WIRE)&#8211; AstraZeneca: Revenue and EPS summary \u00a0 FY 2025 % Change Q4 2025 % Change \u00a0 $m Actual CER1 $m Actual CER &#8211; Product Sales 55,573 9 9 14,538 9 7 &#8211; Alliance Revenue 3,067 39 38 959 34 33 Product Revenue2 58,640 10 10 15,497 10 8 Collaboration Revenue 99 (89) (89) 6 (99) (99) Total Revenue 58,739 9 8 15,503 4 2 Reported EPS ($) 6.60 45 43 1.50 55 47 Core3EPS($) 9.16 12 11 2.12 1 (2) Key performance elements for FY 2025 (Growth numbers at constant exchange rates) Total Revenue up 8% to $58,739m, driven by &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/astrazeneca-results-fy-and-q4-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AstraZeneca results: FY and Q4 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-935461","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AstraZeneca results: FY and Q4 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/astrazeneca-results-fy-and-q4-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca results: FY and Q4 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca results: FY and Q4 2025 Strong commercial performance and excellent pipeline delivery in a continuing catalyst-rich period CAMBRIDGE, England&#8211;(BUSINESS WIRE)&#8211; AstraZeneca: Revenue and EPS summary \u00a0 FY 2025 % Change Q4 2025 % Change \u00a0 $m Actual CER1 $m Actual CER &#8211; Product Sales 55,573 9 9 14,538 9 7 &#8211; Alliance Revenue 3,067 39 38 959 34 33 Product Revenue2 58,640 10 10 15,497 10 8 Collaboration Revenue 99 (89) (89) 6 (99) (99) Total Revenue 58,739 9 8 15,503 4 2 Reported EPS ($) 6.60 45 43 1.50 55 47 Core3EPS($) 9.16 12 11 2.12 1 (2) Key performance elements for FY 2025 (Growth numbers at constant exchange rates) Total Revenue up 8% to $58,739m, driven by &hellip; Continue reading &quot;AstraZeneca results: FY and Q4 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/astrazeneca-results-fy-and-q4-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-10T12:27:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260209280778r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astrazeneca-results-fy-and-q4-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astrazeneca-results-fy-and-q4-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AstraZeneca results: FY and Q4 2025\",\"datePublished\":\"2026-02-10T12:27:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astrazeneca-results-fy-and-q4-2025\\\/\"},\"wordCount\":2106,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astrazeneca-results-fy-and-q4-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260209280778r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astrazeneca-results-fy-and-q4-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astrazeneca-results-fy-and-q4-2025\\\/\",\"name\":\"AstraZeneca results: FY and Q4 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astrazeneca-results-fy-and-q4-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astrazeneca-results-fy-and-q4-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260209280778r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-02-10T12:27:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astrazeneca-results-fy-and-q4-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astrazeneca-results-fy-and-q4-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astrazeneca-results-fy-and-q4-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260209280778r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260209280778r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astrazeneca-results-fy-and-q4-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca results: FY and Q4 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AstraZeneca results: FY and Q4 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/astrazeneca-results-fy-and-q4-2025\/","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca results: FY and Q4 2025 - Market Newsdesk","og_description":"AstraZeneca results: FY and Q4 2025 Strong commercial performance and excellent pipeline delivery in a continuing catalyst-rich period CAMBRIDGE, England&#8211;(BUSINESS WIRE)&#8211; AstraZeneca: Revenue and EPS summary \u00a0 FY 2025 % Change Q4 2025 % Change \u00a0 $m Actual CER1 $m Actual CER &#8211; Product Sales 55,573 9 9 14,538 9 7 &#8211; Alliance Revenue 3,067 39 38 959 34 33 Product Revenue2 58,640 10 10 15,497 10 8 Collaboration Revenue 99 (89) (89) 6 (99) (99) Total Revenue 58,739 9 8 15,503 4 2 Reported EPS ($) 6.60 45 43 1.50 55 47 Core3EPS($) 9.16 12 11 2.12 1 (2) Key performance elements for FY 2025 (Growth numbers at constant exchange rates) Total Revenue up 8% to $58,739m, driven by &hellip; Continue reading \"AstraZeneca results: FY and Q4 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/astrazeneca-results-fy-and-q4-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-10T12:27:06+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260209280778r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/astrazeneca-results-fy-and-q4-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/astrazeneca-results-fy-and-q4-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AstraZeneca results: FY and Q4 2025","datePublished":"2026-02-10T12:27:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/astrazeneca-results-fy-and-q4-2025\/"},"wordCount":2106,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/astrazeneca-results-fy-and-q4-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260209280778r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/astrazeneca-results-fy-and-q4-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/astrazeneca-results-fy-and-q4-2025\/","name":"AstraZeneca results: FY and Q4 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/astrazeneca-results-fy-and-q4-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/astrazeneca-results-fy-and-q4-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260209280778r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-02-10T12:27:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/astrazeneca-results-fy-and-q4-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/astrazeneca-results-fy-and-q4-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/astrazeneca-results-fy-and-q4-2025\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260209280778r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260209280778r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/astrazeneca-results-fy-and-q4-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca results: FY and Q4 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/935461","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=935461"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/935461\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=935461"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=935461"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=935461"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}